Hemogenyx Pharmaceuticals PLC Announces Final Results
Hemogenyx Pharmaceuticals has announced its final results for the year ended 31 December 2020, highlighting significant scientific advancements. Key achievements include the efficacy of HEMO-CAR-T cells against Acute Myeloid Leukemia, development of a new cell-based platform for treating emerging viral diseases, and collaborations with Eli Lilly and the University of Pennsylvania. Post-period, a Master Translational Agreement with the University was established, advancing HEMO-CAR-T towards clinical trials. The CEO emphasized the productivity and diversification of the company’s product pipeline.
- HEMO-CAR-T cells show efficacy against Acute Myeloid Leukemia, both in vitro and in vivo.
- Development of a novel cell-based platform technology (CBR) for emerging viral diseases and certain cancers.
- Agreement with Eli Lilly for developing treatments for autoimmune diseases.
- Sponsored Research Agreement with University of Pennsylvania to advance HEMO-CAR-T toward clinical trials.
- Master Translational Agreement with University of Pennsylvania to further advance HEMO-CAR-T.
- None.
LONDON, UK / ACCESSWIRE / April 30, 2021 / THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Final Results for the Year Ended 31 December 2020
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.
Key Highlights
• Demonstrated that HEMO-CAR-T cells are effective against Acute Myloid Leukemia in vitro and in vivo
• Developed a novel cell-based platform technology, referred to as "CBR," for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer
• Entered into an agreement with Eli Lilly and Company for the development of new treatments of autoimmume diseases
• Entered into Sponsored Research Agreement with the University of Pennsylvania to advance the Company's HEMO-CAR-T product candidate toward clinical trials
Post-Period End Highlights
• Entered into a Master Translational Agreement with the University of Pennsylvania to advance the Company's HEMO-CAR-T product candidate through clinical trials
• The development phase of the Company's collaboration with a leading global pharmaceutical company for the development of its CDX antibody product candidate resulted in the selection of a clone of the antibody that is ready for investigational new drug ("IND") application-enabling studies, a significant step toward clinical trials
Dr Vladislav Sandler, CEO of Hemogenyx, said: "2020 was an exceptionally productive year for Hemogenyx Pharmaceuticals, both scientifically and commercially. Not only did we achieve significant progress with our existing product candidates, we were also able to leverage our proprietary technologies and expertise to further broaden and diversify our product pipeline. We entered into a collaboration with the University of Pennsylvania, thereby advancing HEMO-CAR-T toward clinical trials, completed the developmental stage of our collaboration with GlobalCo by choosing a CDX antibody to be developed into clinical trials, and established a novel platform technology, CBR, for the treatment of a range of conditions including viral infections, in particular COVID-19, as well as certain types of cancer."
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this news release contain forward-looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include without limitation the completion of planned expenditures, the ability to complete exploration programs on schedule and the success of exploration programs. Readers are cautioned not to place undue reliance on the forward-looking information, which speak only as of the date of this news release.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
Click on or paste the following URL into your web browser to view announcement in full:
http://www.rns-pdf.londonstockexchange.com/rns/2813X_1-2021-4-30.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/643531/Hemogenyx-Pharmaceuticals-PLC-Announces-Final-Results
FAQ
What were the key highlights from Hemogenyx Pharmaceuticals' 2020 final results?
Did Hemogenyx Pharmaceuticals enter any significant collaborations in 2020?
What is the significance of the Master Translational Agreement with the University of Pennsylvania?
What is the focus of the new cell-based platform technology developed by Hemogenyx?
